---
document_datetime: 2023-09-21 17:27:19
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/mabthera-epar-all-authorised-presentations_en.pdf
document_name: mabthera-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.945839
conversion_datetime: 2025-12-28 08:36:24.484335
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| EMA Number      | (Invented) name   | Strength   | Pharmaceutical Form                   | Route of Administration   | Immediate Packaging   | Content (concentration)   | Pack size   |
|-----------------|-------------------|------------|---------------------------------------|---------------------------|-----------------------|---------------------------|-------------|
| EU/1/98/067/001 | MabThera          | 100 mg     | Concentrate for solution for infusion | Intravenous use           | Vial (glass)          | 10 ml (10 mg/ml)          | 2 vials     |
| EU/1/98/067/002 | MabThera          | 500 mg     | Concentrate for solution for infusion | Intravenous use           | Vial (glass)          | 50 ml (10 mg/ml)          | 1 vial      |
| EU/1/98/067/003 | MabThera          | 1400 mg    | Solution for injection                | Subcutaneous use          | vial (glass)          | 11.7 ml (120 mg/ml)       | 1 vial      |
| EU/1/98/067/004 | MabThera          | 1600 mg    | Solution for injection                | Subcutaneous use          | vial (glass)          | 13.4 ml (120 mg/ml)       | 1 vial      |